Clinical trials: Immunity to COVID-19
Core Body Temperature in Healthy Subjects, Immune Response to mRNA COVID-19 Vaccination
Fever Tracking Study
The aim of this study is to investigate the feasibility of continuous fever tracking of participants having fever symptoms in a home setting, using a core body temperature (CBT) sensor.
- Trial name
- NCT05475067
- Where
- Switzerland
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Multiple Sclerosis, Autoimmune Blistering Disease
Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients
The purpose of this study is to understand the immune response to coronavirus disease-19 (COVID-19) vaccination in patients on B-cell depleting therapies (BCDT) over time, which in the future may help to inform clinical decision…
- Conditions
- Multiple Sclerosis, Autoimmune Blistering Disease, B-Cell Deficiency
- Trial name
- NCT05286242
- Testing
- COVID19 vaccine
- Where
- United States
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Yale University
Chronic Kidney Disease 5D, Chronic Kidney Disease 5T
Humoral and Cellular İmmune Response to SARS-CoV-2 mRNA BNT162b2 Vaccine in Children With Chronic Kidney Diseases
Coronavirus 2019 (COVID-19) infection is associated with higher morbidity and mortality in adult patients on dialysis, and kidney transplant recipients (KTRs).
- Trial name
- NCT05465863
- Testing
- SARS-CoV-2 mRNA BNT162b2 vaccine (Pfizer-BioNTech®)
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
SARS-CoV-2 Acute Respiratory Disease
Evaluation of the Post-vaccination Immune Response to COVID-19 in the New Caledonian Population
The COVID-19 pandemic caused by SARS-CoV-2 since December 2019 has caused more than 210 million cases worldwide as of September 1, 2021.
- Trial name
- COVCAL (NCT05135585)
- Testing
- Blood sample collection, Questionnaires
- Where
- 3 sites in New Caledonia
- Volunteers
- 680 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
SARS-CoV-2 Vaccination
Adaptive Immune Response to COVID-19 Vaccination
AICOVI (Adaptive Immune Response to COVID-19 Vaccination) is a prospective clinical cohort study aiming at studying the kinetics of vaccine-specific antibody production after COVID-19 vaccination in health care workers.
- Trial name
- AICOVI (NCT04826770)
- Testing
- BNT162b2, AZD 1222, mRNA-1273
- Where
- Germany
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
Covid19, COVID-19 Vaccines
Immune Response to Anti COVID-19 Vaccine in Immunocompromised Patients: a Cohort Study
Despite COVID-19 pandemic having started more than one year ago, there are still limited treatment options for these patients, and over 145 million cases and 3 millions deaths have ensued worldwide.
- Trial name
- NCT04888793
- Testing
- Serologic immune response evaluation
- Where
- Chile
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Pontificia Universidad Catolica de Chile
Covid19, SARS-CoV-2 Infection
A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers
This study will test the COVID-19 vaccine candidate AZD1222 to investigate its safety, tolerability and capability of boosting immune responses both in the blood and the lung when administered to the respiratory tract, in…
- Trial name
- COVAXAER01 (NCT05007275)
- Testing
- 1x10^9 vp AZD1222, 5x10^9 vp AZD1222, 1x10^10 vp AZD1222
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Liver Diseases, Covid19
Safety and Immune Response of COVID-19 Vaccination in Patients With Chronic Liver Diseases
On 11 February 2020, the International Committee for the Classification of Viruses named the disease caused by SAＲS-CoV-2 infection in humans as the new coronavirus pneumonia (coronavirus disease 2019, COVID-19).
- Conditions
- Liver Diseases, Covid19, Adverse Reaction to Vaccine
- Trial name
- SIMPLE (NCT05007665)
- Testing
- SARS-COV-2 VACCINE
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
COVID-19, Sars-CoV2
BCG Vaccination for Healthcare Workers in COVID-19 Pandemic
A novel betacoronavirus, SARS-CoV-2, is spreading rapidly throughout the world. A large epidemic in South Africa may overwhelm available hospital capacity and healthcare resources which would be worsened by absenteeism of…
- Trial name
- NCT04379336
- Testing
- Bacille Calmette-Guérin (BCG)
- Where
- South Africa
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- TASK Applied Science
Covid19
Live Microbials to Boost Anti-Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Immunity Clinical Trial
This pilot double-blind randomized controlled trial will test the preliminary efficacy of two doses of a combination of live microbials (probiotics) given to boost the immunity of unvaccinated persons previously infected with…
- Trial name
- NCT04847349
- Testing
- OL-1, standard dose, OL-1, high dose
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above
This study is assessing the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when it is co-administered with a COVID-19 messenger ribonucleic acid (mRNA) vaccine (Omicron XBB.1.5), compared to…
- Trial name
- NCT06374394
- Testing
- RSVPreF3 OA investigational vaccine, COVID-19 mRNA vaccine
- Where
- 24 sites in United States, Belgium and 2 more
- Volunteers
- 841 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19, SARS-CoV-2 Infection
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
The goal of this clinical trial is to test two investigational COVID-19 booster vaccines, called CoTend-s3BXBB and CoTend-BXBB, in healthy volunteers ages 40-64.
- Trial name
- CONTENDER (NCT06810934)
- Testing
- CoTend-BXBB (SARS2-30404), CoTend-s3BXBB (SARS2-17032)
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Kara Chew
Covid19
ImmuneRACE - Immune Response Action to COVID-19 Events
ImmuneRACE is a study, which is designed to better understand the immune response to COVID-19. This is critically important because the immune system may be able to tell us important information about how our own bodies detect…
- Trial name
- NCT04494893
- Where
- United States
- Volunteers
- 808 people, healthy volunteers welcome
- Sponsor
- Adaptive Biotechnologies
COVID-19
A Study to Evaluate the Ability of UB-612 COVID-19 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines.
This is a study to evaluate the ability of UB-612 vaccine to boost immunity of subjects who previously received two doses of AstraZeneca COVID-19 vaccine (ChAdOx1-S) with an 8-16 week interval between first and second doses.
- Trial name
- NCT05167253
- Testing
- UB-612
- Volunteers
- healthy volunteers welcome
- Sponsor
- United Biomedical Inc., Asia
Vaccination; Infection, Covid19
Immune Response to Vaccination Against Covid-19, a Follow up Study
The study investigates the immune response after vaccination in individuals with and without pre-existing immunity to Coronavirus disease (COVID) -19. The participants are followed and sampled up to 4 years after vaccination.
- Trial name
- CoVacc (NCT04920357)
- Testing
- Vaccination
- Where
- 5 sites in Sweden
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Umeå University
SARS-CoV-2
Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19)
A total of 300 healthy volunteers between the ages of 18 and 80 with no previous history of COVID-19 will be entered into the study and will receive IPV by injection on Day 1.
- Trial name
- NCT04639375
- Testing
- Vaccinated with polio vaccine (IPV)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- E-MO Biology Inc
Immunology, Allergy
Impaired Type I IFN Immunity Due to Autoantibodies or a Genetic Defect: a Prospective National Cohort
The major role of human genetic factors in the immune response to infections is now well established, particularly for viral infections.
- Conditions
- Immunology, Allergy, Genetic Diseases, Infectious Diseases
- Trial name
- COVIFERON (NCT06762002)
- Testing
- blood sample
- Where
- 9 sites in France
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Covid19, Respiratory Viral Infection
The Evaluation of Cellular and Humoral Immunity to COVID-19 in Moscow Residents
The aim of the research is to estimate the levels of cellular and humoral immunity to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among Moscow residents over 18 years old.
- Trial name
- NCT04898140
- Testing
- SARS-CoV-2 specific IgM and IgG detection, ELISpot: detection of the T cells specific to different SARS-CoV-2 proteins, Flow cytometry: detection of the SARS-CoV-2 specific T-helpers and cytotoxic T lymphocytes
- Where
- Russia
- Volunteers
- 5,340 people, healthy volunteers welcome
- Sponsor
- Moscow Department of Health
COVID-19, Serology
Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms
Three hundred healthcare workers with mild symptoms for Covid-19 will be followed during three months. Each two weeks, serological tests will be performed. Re-infection will be monitored by saliva-swabs.
- Trial name
- NCT04356586
- Where
- Belgium
- Volunteers
- 287 people, healthy volunteers welcome
- Sponsor
- Sciensano
COVID - 19
Retail COVID-19 Study
Despite the availability of vaccines, there remains a need to identify specific immune responses that correlate with protection against SARS-CoV-2 infection.
- Trial name
- NCT06761612
- Testing
- FDA approved mRNA vaccines
- Where
- 20 sites in United States
- Volunteers
- 2,519 people, healthy volunteers welcome
- Sponsor
- Biomedical Advanced Research and Development Authority